Managing the neuropsychiatric complications of hepatitis C treatment

British Journal of Hospital Medicine

Volumn 68, Issue 10, 2007, Pages 520-525

  Sockalingam, Sanjeev ^a   Shainmi, Chekkera ^a,b   Stergiopoulos, Vicky ^b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c St Michael's Hospital

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; LITHIUM; MIRTAZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; PAROXETINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; VALPROIC ACID;

ANXIETY; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DRUG MECHANISM; HAMILTON SCALE; HEPATITIS C; HUMAN; MANIA; PSYCHOSIS; RISK FACTOR; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

EID: 35548944089     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2007.68.10.27321     Document Type: Conference Paper

References (43)

1. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M (2002a) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72: 237-41
2. Bonaccorso S, Marino V, Puzella A et al (2002b) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmocol 22: 86-90
3. Capuron L, Gumnick JF, Musselman DL et al (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 26: 643-52
4. Capuron L, Neurauter G, Musselman DL et al (2003) Interferon-alpha- induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 54: 906-14
5. Constant A, Castera L, Dantzer R et al (2005) Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66: 1050-7
6. Dieperink E, Willenbring ML, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 157: 867-76
7. Dieperink E, Ho SB, Thuras O, Willenbring ML (2003) A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44: 104-12
8. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML (2004) Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych 26: 237-40
9. El-Sarag HB, Kunik M, Richardson P, Rabaneck L (2002) Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 123: 476-82
10. Farber GA, Levin T, White CA (2005) A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. Gen Hosp Psychiatry 27: 329-37
11. Fattovich G, Giustina G, Favarato S, Ruol A (1996) A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24: 38-47
12. Felker BL, Sloan KL, Dominitz JA, Barnes RF (2003) The safety of valproic acid use for patients with hepatitis infection. Am J Psychiatry 160: 174-8
13. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG (2004) Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 45: 29-33
14. Gleason OC, Yates WR, Philipsen MA (2005) Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry 7: 225-30
15. Hadziyannis SJ, Sette H, Morgon TR et al (2004) Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 140: 346-55
16. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E (2001) Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 96: 157-64
17. Horikawa N, Ymazaki T, Izumi N, Uchihara M (2003) Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych 25: 34-8
18. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H (2000) Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 54: 565-72
19. Janssen HLA, Brouwer JT, Mast RCVD, Schalm SW (1994) Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21: 241-3
20. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M (2002) Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16: 1091-9
21. Kraus MR, Shafer A, Faller H, Csef H, Scheurlen M (2003) Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64: 1769-74
22. Kraus MR, Schafer A, Al-Taie O, Scheurlen M (2005) Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis 12: 96-100
23. Maddock C, Baita A, Orru MG et al (2004) Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 18: 41-6
24. Morikawa O, Sakia N, Obara H, Saito N (1998) Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349: 317-24
25. Musselman DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-6
26. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ (2004) Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 161: 429-35
27. Raison CL, Borisov AS, Broadwell SD et al (2005) Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66: 41-8
28. Renault PF, Hoofnagle JH, Park Y (1987) Psychiatric complications of long term interferon alfa therapy. Arch Intern Med 147: 1577-80
29. Rifai MA, Moles JK, Short DD (2006) Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 57: 570-2
30. Scalori A, Pozzi M, Bellia V et al (2005) Interferon-induced depression: prevalence and management. Dig Liver Dis 37: 102-7
31. Schaefer M, Engelbrecht MA, Gut O (2002) Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26: 731-46
32. Schaefer M, Schmidt F, Folwaczny C et al (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric groups. Hepatology 37: 443-51
33. Schaefer M, Schwaiger M, Garkisch AS et al (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42: 793-8
34. Schramm TM, Lawford BP, Macdonald GA, Cooksley WGE (2000) Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 173: 359-61
35. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R (1997) Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747: 348-51
36. Sockalingam S, Balderson K (2005) Major depressive episode with psychotic features induced pegylated interferon-alpha-2b and ribavirin treatment. Int Clin Psychopharmacol 20: 289-90
37. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management and treatment of hepatitis C. Hepatology 39: 1147-71
38. Telio D, Sockalingam S, Stergiopoulos V (2006) Persistent psychosis after treatment with interferon alfa: a case report. J Clin Psychopharmacol 26: 446-7
39. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P (1995) Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 7: 165-8
40. Weinrieb RM, Auriacombe M, Lynch KG, Chang KM, Lewis JD (2003) A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 64: 1502-10
41. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10: 538-44
42. World Health Organization (1997) Hepatitis C: global prevalence. Wkly Epidemiol Rec 72: 341-4
43. Yovtcheva SP, Rifai MA, Moles JK, Linden BJVD (2001) Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 42: 411-15